These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 12901225)

  • 41. The level of telomere dysfunction determines the efficacy of telomerase-based therapeutics in a lung cancer cell line.
    Pantic M; Zimmermann S; Waller CF; Martens UM
    Int J Oncol; 2005 May; 26(5):1227-32. PubMed ID: 15809713
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vivo regulation of telomerase activity and telomere length.
    Hathcock KS; Jeffrey Chiang Y; Hodes RJ
    Immunol Rev; 2005 Jun; 205():104-13. PubMed ID: 15882348
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Telomerase inhibitors and 'T-oligo' as cancer therapeutics: contrasting molecular mechanisms of cytotoxicity.
    Rankin AM; Faller DV; Spanjaard RA
    Anticancer Drugs; 2008 Apr; 19(4):329-38. PubMed ID: 18454043
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Assembly of mutant-template telomerase RNA into catalytically active telomerase ribonucleoprotein that can act on telomeres is required for apoptosis and cell cycle arrest in human cancer cells.
    Goldkorn A; Blackburn EH
    Cancer Res; 2006 Jun; 66(11):5763-71. PubMed ID: 16740715
    [TBL] [Abstract][Full Text] [Related]  

  • 45. How telomerase reaches its end: mechanism of telomerase regulation by the telomeric complex.
    Bianchi A; Shore D
    Mol Cell; 2008 Jul; 31(2):153-65. PubMed ID: 18657499
    [TBL] [Abstract][Full Text] [Related]  

  • 46. How to inhibit telomerase activity for cancer therapy.
    Kyo S; Inoue M
    Curr Med Chem Anticancer Agents; 2002 Sep; 2(5):613-26. PubMed ID: 12678728
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Telomere dysfunction and telomerase activation in cancer--a pathological paradox?
    Calcagnile O; Gisselsson D
    Cytogenet Genome Res; 2007; 118(2-4):270-6. PubMed ID: 18000380
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Telomeres and telomerase as targeted therapies in cancer treatment].
    Souiden Y; Bouraoui A; Chaieb K; Mahdouani K
    Bull Cancer; 2010 Sep; 97(9):1087-104. PubMed ID: 20663741
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Telomere-based cancer treatment: emerging targeted therapies.
    Chen M; McLeskey SW
    Clin J Oncol Nurs; 2010 Dec; 14(6):720-6. PubMed ID: 21112850
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer.
    Hochreiter AE; Xiao H; Goldblatt EM; Gryaznov SM; Miller KD; Badve S; Sledge GW; Herbert BS
    Clin Cancer Res; 2006 May; 12(10):3184-92. PubMed ID: 16707619
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Correlation of telomerase activity and telomere length to chemosensitivity.
    Kiyozuka Y
    Methods Mol Med; 2005; 111():97-108. PubMed ID: 15911975
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Telomerase inhibitors for the treatment of cancer: the current perspective.
    Perry PJ; Arnold JR; Jenkins TC
    Expert Opin Investig Drugs; 2001 Dec; 10(12):2141-56. PubMed ID: 11772310
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Agents that target telomerase and telomeres.
    Raymond E; Sun D; Chen SF; Windle B; Von Hoff DD
    Curr Opin Biotechnol; 1996 Dec; 7(6):583-91. PubMed ID: 8939642
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Telomerase inhibition, oligonucleotides, and clinical trials.
    Corey DR
    Oncogene; 2002 Jan; 21(4):631-7. PubMed ID: 11850789
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Telomeres and telomerase in chronic myeloid leukaemia: impact for pathogenesis, disease progression and targeted therapy.
    Keller G; Brassat U; Braig M; Heim D; Wege H; Brümmendorf TH
    Hematol Oncol; 2009 Sep; 27(3):123-9. PubMed ID: 19569255
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Human protection of telomeres 1 (POT1) is a negative regulator of telomerase activity in vitro.
    Kelleher C; Kurth I; Lingner J
    Mol Cell Biol; 2005 Jan; 25(2):808-18. PubMed ID: 15632080
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Telomerase: biology and phase I trials.
    Kelland LR
    Lancet Oncol; 2001 Feb; 2(2):95-102. PubMed ID: 11905801
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Telomeres, telomerase and cancer].
    Soria JC; Rixe O
    Bull Cancer; 1997 Oct; 84(10):963-70. PubMed ID: 9435798
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mutated telomeres sensitize tumor cells to anticancer drugs independently of telomere shortening and mechanisms of telomere maintenance.
    Cerone MA; Londoño-Vallejo JA; Autexier C
    Oncogene; 2006 Nov; 25(56):7411-20. PubMed ID: 16767163
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Telomerase as a clinical target: current strategies and potential applications.
    Fleisig HB; Wong JM
    Exp Gerontol; 2007; 42(1-2):102-12. PubMed ID: 16814507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.